Celebrex On The “Rebound,” Pfizer Says

Celebrex has nearly regained the market share it lost during the COX-2 inhibitor safety controversy, Pfizer said Jan. 19

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet